Review anchor
RAF serine/threonine protein kinase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
RAF serine/threonine protein kinase
CHEMBL3559685
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RAF serine/threonine protein kinase as ChEMBL target CHEMBL3559685, mapped to UniProt P04049. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3559685
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04049
RAF proto-oncogene serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why RAF serine/threonine protein kinase matters
RAF serine/threonine protein kinase is reviewed as RAF proto-oncogene serine/threonine-protein kinase (UniProt P04049); RAF serine/threonine protein kinase shows approved-linked disease relevance led by low grade glioma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 2 compounds, and 1 assay, with lead potency reaching pChEMBL 6.0.
Protein context
RAF proto-oncogene serine/threonine-protein kinase
RAF proto-oncogene serine/threonine-protein kinase Sequence length is 648 aa.
Review this target as RAF serine/threonine protein kinase, mapped to UniProt P04049. ChEMBL maps the protein component as RAF proto-oncogene serine/threonine-protein kinase. Sequence length is 648 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P04049
Protein
Disease context
low grade glioma
RAF serine/threonine protein kinase shows approved-linked disease relevance led by low grade glioma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TOVORAFENIB.
Start review with low grade glioma because it currently carries approved-linked support. Linked drugs include TOVORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 2 compounds, and 1 assay for this target. The dominant activity type is IC50. CHEMBL3934468 is the current potency anchor at pChEMBL 6.0.
Use CHEMBL3934468 as the tractability anchor when discussing potency (pChEMBL 6.0).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 6.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why RAF serine/threonine protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04049, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why low grade glioma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2
Total Compounds
1
Total Assays
0
Approved Drugs
IC50: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3934468
|
6.0 | IC50 | — |
Source Header